Monroe facility FDA observations unresolved
The Monroe facility has five FDA observations; management is awaiting FDA response and hopes to restart commercial manufacturing this year, but timeline is uncertain.
high · analyst_question
Glenmark Pharmaceuticals Limited — Q1 FY26
Glenmark's Q1 FY26 consolidated revenue was INR 32,644 million, up 0.6% YoY, with India formulation growing 3.7% and North America up 8.9% QoQ to $91M.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Antitrust litigation in US
Glenmark USA is involved in multidistrict antitrust litigation; settled with direct purchaser class for $37.75M, but other classes remain, with no visibility on timeline.
medium · management_commentaryIndia reported growth vs secondary sales divergence
India reported growth of 3.7% lags secondary sales growth of 15.1% due to tail-end brand discontinuations; convergence expected only from Q3.
medium · analyst_questionNet debt increase and working capital buildup
Net debt increased to INR 1,500 crore due to inventory buildup for launches and one-time payments; management expects stabilization but no specific timeline.
low · data_observation